DiaMedica Corp (DMAC) - מקדם חוב לטווח ארוך להון

DiaMedica Therapeutics (DMAC) is developing a closed-loop therapy system for renal and neurological pathologies, protected from generics by a unique protein. Business stability currently relies on the DM199 patent and clinical trial results. This daily price action with the 0.00 indicator is illustrated below. The issuer's cash flow is based on funding the development of new treatment methods for vascular lesions of the brain and kidneys.

This indicator measures the proportion of liabilities with a maturity exceeding one year relative to equity, allowing for the differentiation of strategic borrowing from capitalization volatility. By analyzing the long-term debt-to-equity profile, an investor can assess the financial stability of DiaMedica Therapeutics (DMAC) during the critical testing phase of the DM199 drug, where the balance between credit load and cash burn determines the biotech's survival.